Retatrutide
Neutral technical record and index of the peer-reviewed literature referencing Retatrutide. For research use only — no human or veterinary use, benefit, or dosing information is provided.
What it is
Retatrutide is a synthetic peptide that acts as a single-molecule agonist at three receptors. It belongs to the class of multi-receptor incretin agonists, targeting the GIP, GLP-1, and glucagon receptors. It is supplied as lyophilized material for research use only.
Mechanism (technical)
Retatrutide has been studied for its combined agonist action on GIP, GLP-1, and glucagon receptors, pathways associated with glucose regulation and energy metabolism. This triple-receptor mechanism has been investigated in metabolic clinical trials. Endpoints have characterized body weight, HbA1c, and body composition.
Peer-reviewed literature
4 studies indexed · 4 human. Listed neutrally; outcome studies are indexed, not endorsed.
- Effects of retatrutide on body composition in people with type 2 diabetesCoskun T, et al. · 2025 · Lancet Diabetes Endocrinol · RCT · human
- Once-weekly retatrutide on weight and metabolic markers: systematic review and meta-analysis of RCTsPasqualotto E, et al. · 2024 · Metabol Open · meta-analysis · human
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trialRosenstock J, et al. · 2023 · Lancet · RCT · human
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialJastreboff AM, et al. · 2023 · N Engl J Med · RCT · human
For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or dietary supplement. Sold to qualified researchers for laboratory research purposes only.